This Fox Chase professor participates in the Undergraduate Summer Research Fellowship.
Learn more about Research Volunteering.
Read the latest updates about the COVID-19 vaccine at Fox Chase →
Michael J. Hall, MD, MS
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Lab Staff
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
About
Chair, Department of Clinical Genetics
Professor, Department of Clinical Genetics
Director, Gastrointestinal Risk Assessment
Co-Leader, Cancer Prevention and Control Program
NCCN, Genetic Colorectal/Colorectal Cancer Screening Panel Member
Specialties
Treatment Focus
- Gastrointestinal oncology/medical oncology
- Cancer risk assessment for cancers of the gastrointestinal tract
- Cancer risk assessment for endocrine cancers and genitourinary cancers
Research Program
Key Awards
Medical Oncology
Treatment Philosophy
I am a GI oncologist and a clinical cancer geneticist, and I have found over the years that my strongest skills are in helping my patients and their families to understand the complicated risks of cancer screening, surgery and treatment, to weigh the different options for treatment, and finally to develop a plan that is both in line with cutting edge research but also with their personal needs and preferences for their health and their lives. In cancer medicine, there is no longer a one size fits all approach, and in my practice I strive to build on my patients’ unique strengths and to further bring the multi-faceted expertise of my colleagues at Fox Chase and my colleagues nationally to offer each of my patients the best care I possibly can.
Education and Training
Educational Background
- MS, Health Studies, University of Chicago Medical Center, Chicago, IL, 2006
- Fellowship, Hematology/Oncology, University of Chicago, Chicago, IL 2002-2005
- Residency, Internal Medicine, Harvard/Brigham and Women's Hospital, Boston, MA 1999-2002
- MD, Columbia College of Physicians & Surgeons, New York, NY, 1999
- BA, French Literature, Columbia University, New York, NY, 1993
Certifications
- Board Certified in Medical Oncology
- Pennsylvania Medical License
Memberships
- American Cancer Society
- American Society of Clinical Oncology
- Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC)
- Research Review Committee, Fox Chase Cancer Center
Honors & Awards
- Philadelphia Magazine Top Doctors, 2015-20
- Best Doctors in America® , 2019-2020, Medical Oncology and Hematology
- Main Line Today Top Doctors, 2019
- America's Top Doctors®, 2017
- Mentored Research Scholar Grant, American Cancer Society, 2007
- Young Investigator Award, American Society of Clinical Oncology, 2006
- Merit Award, American Society of Clinical Oncology, 2003-2005
- Honorary Alpha Omega Alpha, University of Chicago, 2004
- Excellence in Teaching Award, Harvard Medical School, 2001
- Alpha Omega Alpha, Columbia College of Physicians/Surgeons, 1999
Patient Stories
Alan Zlatkin
Pancreatic Cancer
Alan Zlatkin
Pancreatic Cancer
Being defeated is a matter of perspective and will. I feel that no matter how serious the illness is, I can overcome it with the right help and the right attitude.
Jennifer O’Farrell
Colorectal Cancer
Jennifer O’Farrell
Colorectal Cancer
Unfortunately, because of COVID-19 precautions, my kids couldn’t be with me when I rang the bell to celebrate my last treatment in May. However, I was able to finish treatment with all the same nurses and staff who were there from the very beginning. They became like family to me.
Karin McAnlis
Pancreatic Cyst
Karin McAnlis
Pancreatic Cyst
I am BRCA1 and BRCA2 positive, meaning I have mutations in those two genes that make me more susceptible to cancer. When I was 67 years old, I was diagnosed with premalignant pancreatic cysts and anal cancer in the same year.
Daryl Lloyd
Colorectal Cancer
Daryl Lloyd
Colorectal Cancer
Working for the Willingboro School District in New Jersey and the Colonial School District in Delaware, as an educator for over 25 years, I know the value of good health insurance. I never took for granted the benefits provided to me by the state, and that meant making sure I routinely got a colonoscopy. They aren’t fun, but they might save your life – they saved mine.
Lauren Ricottone
Colorectal Cancer
Lauren Ricottone
Colorectal Cancer
As a nurse, I thought I had a good handle on my health. But in 2015, I went for a colonoscopy because I’d been experiencing rectal bleeding, and instead of a diagnosis I got the surprise of a lifetime.
Pages
Research Profile
Research Program
Research Interests
- Hereditary cancer risk for gastrointestinal cancers
- Lynch syndrome, microsatellite instability, polyposis syndromes, DNA repair
- Genetic and genomic testing in cancer patients
- Communication of genetic risk information to patients and physicians
- Health disparities related to genetic and genomic testing
- Genetic basis of cancer, especially cancer in young adults
Lab Overview
Since 1991, the Risk Assessment Program has received strong support from its clinical and research participants and referring providers. Over 11,000 patients have joined RAP’s registry and donated epidemiologic data and a biospecimen (~8,000 blood donations). This valuable resource is available to FCCC investigators and the wider genetics community and has generated significant grant support, publications, and presentations at national/international venues. RAP, the research component of the Department of Clinical Genetics, is part of the FCCC Cancer Prevention and Control (CPC) program. RAP maintains close collaborations with clinical, behavioral, and laboratory scientists with research interests in genetic risk and cancer prevention. RAP administers studies of the biological, genetic and environmental factors that influence cancer risk. RAP has established a unique registry of family data, blood, and tissue samples that is used to study the genetic basis of cancer. Our work is supported by funding from governmental, foundation, industry, and philanthropic sources and has contributed significantly to the field.
My group’s research is in three areas related to GI genetic risk and risk assessment. My primary syndrome of expertise and study is Lynch syndrome, but I have also performed research among all high risk GI patients, patients with hereditary breast/ovarian cancer and BRCA1/2 mutations, hereditary pancreatic cancer, high risk renal cell cancers, and others:
- Characterization of genetic risks associated with germline genes and molecular genetic changes that increase cancer risks including gene discovery. Our research has included studies to characterize the spectrum of cancer risk associated with hereditary risk genes, studies in high risk patients recruited through our Risk Assessment Program database to identify new cancer risks, and characterization of molecular risks in high risk patients such as TMB, MSI, and others.
- Communication of genetic risks to patients, whether related to novel tests (tumor genomic testing), novel pathways for communication of genetic risk information (telephone, online, etc), and supports for communication.
- Disparities associated with risk assessment and clinical genetics testing awareness, access, utilization, communication of results in families, and use of preventive screening.
Lab Staff
Alison Conn
Practice Manager
Eric Tetzlaff
PA-C –Physician Assistant
Yana Chertock, MA, CCRP
Research Coordinator
Hannah R. Campbell, ScM, LCGC
Cancer Genetic Counselor
Michelle McSweeny, MS, LCGC
Cancer Genetic Counselor
Catherine Neumann, MS, LCGC
Cancer Genetic Counselor
Kim Rainey, MS, LCGC
Cancer Genetic Counselor
Publications
Selected Publications
Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal E, Singh NA, Lancaster JM, Kurian AW. Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Accepted for publication January 2021, Cancer Prevention Research
Hall MJ. Updates in Chemoprevention Research for Hereditary Gastrointestinal and Polyposis Syndromes. Current Treatment Options in Gastroenterology. CTOG-D-20-00028R1. 8.2020.
Tricarico R, Nicolas E, Hall MJ, Golemis EA. X- and Y-linked chromatin-modifying genes as regulators of sex-specific cancer incidence and prognosis. Clin Cancer Res, 2020.
Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship Between MLH, PMS2, MSH2, and MSH6 Gene Specific Alternations and Tumor Mutation Burden (TMB) in 1,057 Microsatellite Instability-high Solid Tumors. Int J Cancer. 2020 May 24. doi: 10.1002/ijc.33115. [Epub ahead of print]. PMID: 32449172.
Hampel H, Chruch J, Dudley BR, Hall MJ, Stoffel E, Yurgelun MB, Kupfer S, Singh A, You YN, Mork ME, Stoll JLK. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position Statement on Multigene Panel Testing for Patients with Colorectal Cancer and/or Polyposis. Fam Cancer. 2020 Jul;19(3):223-239. doi: 10.1007/s10689-020-00170-9.PMID: 32172433
Biller L, Ukaegbu C, Dhingra T, Burke C, Chertock Y, Chittenden A, Church J, Koeppe E, Leach B, Levinson E, Lim R, Lutz M, Salo-Mullen E, Sheikh R, Idos G, Kastrinos F, Stoffel E, Weiss J, Hall MJ, Kalady M, Stadler Z, Syngal S, Yurgelun M. A Multi-Institutional Cohort of Therapy-associated Polyposis in Childhood and Young Adulthood Cancer Survivors. Canc Prev Res. 2020 Feb 12. Doi: 10.1158/1940-6207. CAPR-19-0416R1. PMID: 32051178.
Golan T et al, Hall MJ. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence with Metastatic Pancreatic Cancer Screened for Entry into the POLO Trial. Clin Oncol. 2020 Feb 19: JCO1901890. doi: 10.1200/JCO.19.01890. PMID: 32073954.
Jain R, Handorf E, Khare V, Blau M, Chertock Y, Hall MJ. Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants. Oncologist. 2020 Feb; 25 (2): 161-169. doi: 10.1634/theoncologist.2019-0289.Epub 2019 Nov 20. PMID: 32043776.
Nicolas E, Tricarico R, Savage M, Golemis EA, Hall MJ. Disease-Associated Genetic Variation in Human Mitochondrial Protein Import. American Journal of Human Genetics, 2019. PubMed
Golan T, Hammel P, Reni M, Van Cutsem E, Hall MJ, et all. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2. PMID: 31157963; PMCID: PMC6810605.
Hall MJ et al. The COGENT study group. Use and patient reported outcomes of clinical multi-gene panel testing for cancer susceptibility in the multi-center Communication of Genetic Test Results by Telephone Study. JCO Precision Oncology.Dec.2018.00199.
Gray PN, Tsai P, Chen D, Wu S, Hoo J, Hall MJ, et al. TumorNext-Lynch-MMR: A Comprehensive Next Generation Sequencing Assay for the Detection of Germline and Somatic Mutations in Genes Associated with Mismatch Repair Deficiency and Lynch Syndrome. Oncotarget. 2018 Apr 17;9(29):20304-20322. PMID: 29755653; PMCID: PMC5945525.
Shaikh T, Handorf EA, Meyer JE, Hall MJ, Esnaola NF. Mismatch Repair Deficiency Testing in Patients with Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol. 2018 Feb 8;4(2):e173580. PMID: 29121143; PMCID: PMC5838708.
Kurian AW, Hughes E, Handorf EA, Gutin, A, Allen B, Hartman AR, Hall, MJ. Breast and Ovarian Cancer Penetrance Estimates Derived from Germline Multiple –Gene Sequencing Results in Women. JCO Precision Oncology 2017. June 27.10.1200.00066.
Meyer JE, Cohen SJ, Ruth KJ, Sigurdson ER, Hall MJ. Young Age Increases Risk of Lymph Node Positivity in Early-Stage Rectal Cancer. J Natl Cancer Inst. 2016 Jan;108(1) PubMed PMID: 26719881; PubMed Central PMCID: PMC4715232
Arora S, Yan H, Cho I, Fan HY, Luo B, Gai X, Hall M, et al. Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes from a Subset of Patients With Familial Colorectal Carcinomas. Gastroenterology. 2015 Dec;149(7):1872-1883.e9. doi: 10.1053/j.gastro.2015.08.052. Epub 2015 Sep 5. PMID: 26344056; PMCID: PMC4663158.
Guindalini RS, Win AK, Gulden C, Lindor NM, Hall MH, et all. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov;149(6):1446-53. doi: 10.1053/j.gastro.2015.07.052. Epub 2015 Aug 3. PMID: 26248088; PMCID: PMC4648287.
Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Hall, MJ. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget. 2015 Nov 24;6(37):39614-33. doi: 10.18632/oncotarget.5554. PMID: 26485759; PMCID: PMC4741850.
Boland PM, Ruth K, Matro JM, Rainey KL, Fang CY, Wong YN, Daly MB, Hall MJ. Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing. Clin Genet. 2015 Dec;88(6):565-72. doi: 10.1111/cge.12555. Epub 2015 Jan 22. PMID: 25523111; PMCID: PMC4474774.
Hall MJ, Innocent J, Rybak CM, Veloski C, Scott WJ, et all. Case Report: Bilateral granulosa cell carcinoma: A novel malignant manifestation of MEN1 syndrome associated with a rare intronic deletion. Appl Clin Gen 2014. PubMed
Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB. Understanding patient and provider perceptions and expectations of genomic medicine. J Surg Oncol. 2015 Jan;111(1):9-17. doi: 10.1002/jso.23712. Epub 2014 Jul 3. PMID: 24992205; PMCID: PMC4286413.
Bradbury AR, Patrick-Miller L, Long J, Stopfer J, Hall MJ et all. Development of a tiered and binned counseling model for informed consent in the era of multiplex testing for cancer susceptibility Genet Med. 2014 Oct 9. PubMed
Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014 Sep;12(9):1339-1346. PubMed
Hall MJ. Conflicted Confidence: Academic Oncologists' Views on Multiplex Pharmacogenomic Testing. J Clin Oncol. 2014 Mar 24. PubMed
Hall MJ, Herda MM, Handorf EA, Rybak CC, Keleher CA, Siemon M, Daly MB. Direct access to universal mismatch repair (MMR) screening results for Lynch syndrome (LS) via electronic personal health record (ePHR):A feasibility study. Genet Med. 2014 May 1.
Matro JM, Ruth KJ, Wong YN, McCully KC, Rybak CM, Meropol NJ, Hall MJ. Cost-sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing. J Genet Couns. 2014 May 6.
Hall MJ, Manne SL, Myers RE, Keenan EM, Balshem AM, Weinberg DS. Association of knowledge and race to gene environment risk assessment (GERA) testing for colorectal cancer Genome Med 2012;4(11):92 [epub ahead of print] PMID: 23194586.
Hall MJ, Ruth K, Giri VN. Predictors of compliance with age-appropriate colorectal cancer screening in men enrolled in a prostate cancer screening program. Cancer 2012 Jan 15;118(2):478-84.
Additional Publications
Contact Information
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Contact Information
Chair, Department of Clinical Genetics
Professor, Department of Clinical Genetics
Director, Gastrointestinal Risk Assessment
Co-Leader, Cancer Prevention and Control Program
NCCN, Genetic Colorectal/Colorectal Cancer Screening Panel Member
Treatment Focus
- Gastrointestinal oncology/medical oncology
- Cancer risk assessment for cancers of the gastrointestinal tract
- Cancer risk assessment for endocrine cancers and genitourinary cancers
Research Program
Key Awards
Medical Oncology
Treatment Philosophy
I am a GI oncologist and a clinical cancer geneticist, and I have found over the years that my strongest skills are in helping my patients and their families to understand the complicated risks of cancer screening, surgery and treatment, to weigh the different options for treatment, and finally to develop a plan that is both in line with cutting edge research but also with their personal needs and preferences for their health and their lives. In cancer medicine, there is no longer a one size fits all approach, and in my practice I strive to build on my patients’ unique strengths and to further bring the multi-faceted expertise of my colleagues at Fox Chase and my colleagues nationally to offer each of my patients the best care I possibly can.
Education
Educational Background
- MS, Health Studies, University of Chicago Medical Center, Chicago, IL, 2006
- Fellowship, Hematology/Oncology, University of Chicago, Chicago, IL 2002-2005
- Residency, Internal Medicine, Harvard/Brigham and Women's Hospital, Boston, MA 1999-2002
- MD, Columbia College of Physicians & Surgeons, New York, NY, 1999
- BA, French Literature, Columbia University, New York, NY, 1993
Certifications
- Board Certified in Medical Oncology
- Pennsylvania Medical License
Memberships
- American Cancer Society
- American Society of Clinical Oncology
- Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC)
- Research Review Committee, Fox Chase Cancer Center
Honors & Awards
- Philadelphia Magazine Top Doctors, 2015-20
- Best Doctors in America® , 2019-2020, Medical Oncology and Hematology
- Main Line Today Top Doctors, 2019
- America's Top Doctors®, 2017
- Mentored Research Scholar Grant, American Cancer Society, 2007
- Young Investigator Award, American Society of Clinical Oncology, 2006
- Merit Award, American Society of Clinical Oncology, 2003-2005
- Honorary Alpha Omega Alpha, University of Chicago, 2004
- Excellence in Teaching Award, Harvard Medical School, 2001
- Alpha Omega Alpha, Columbia College of Physicians/Surgeons, 1999
Research Profile
Research Interests
- Hereditary cancer risk for gastrointestinal cancers
- Lynch syndrome, microsatellite instability, polyposis syndromes, DNA repair
- Genetic and genomic testing in cancer patients
- Communication of genetic risk information to patients and physicians
- Health disparities related to genetic and genomic testing
- Genetic basis of cancer, especially cancer in young adults
Lab Overview
Since 1991, the Risk Assessment Program has received strong support from its clinical and research participants and referring providers. Over 11,000 patients have joined RAP’s registry and donated epidemiologic data and a biospecimen (~8,000 blood donations). This valuable resource is available to FCCC investigators and the wider genetics community and has generated significant grant support, publications, and presentations at national/international venues. RAP, the research component of the Department of Clinical Genetics, is part of the FCCC Cancer Prevention and Control (CPC) program. RAP maintains close collaborations with clinical, behavioral, and laboratory scientists with research interests in genetic risk and cancer prevention. RAP administers studies of the biological, genetic and environmental factors that influence cancer risk. RAP has established a unique registry of family data, blood, and tissue samples that is used to study the genetic basis of cancer. Our work is supported by funding from governmental, foundation, industry, and philanthropic sources and has contributed significantly to the field.
My group’s research is in three areas related to GI genetic risk and risk assessment. My primary syndrome of expertise and study is Lynch syndrome, but I have also performed research among all high risk GI patients, patients with hereditary breast/ovarian cancer and BRCA1/2 mutations, hereditary pancreatic cancer, high risk renal cell cancers, and others:
- Characterization of genetic risks associated with germline genes and molecular genetic changes that increase cancer risks including gene discovery. Our research has included studies to characterize the spectrum of cancer risk associated with hereditary risk genes, studies in high risk patients recruited through our Risk Assessment Program database to identify new cancer risks, and characterization of molecular risks in high risk patients such as TMB, MSI, and others.
- Communication of genetic risks to patients, whether related to novel tests (tumor genomic testing), novel pathways for communication of genetic risk information (telephone, online, etc), and supports for communication.
- Disparities associated with risk assessment and clinical genetics testing awareness, access, utilization, communication of results in families, and use of preventive screening.
Lab Staff
Alison Conn
Practice Manager
Eric Tetzlaff
PA-C –Physician Assistant
Yana Chertock, MA, CCRP
Research Coordinator
Hannah R. Campbell, ScM, LCGC
Cancer Genetic Counselor
Michelle McSweeny, MS, LCGC
Cancer Genetic Counselor
Catherine Neumann, MS, LCGC
Cancer Genetic Counselor
Kim Rainey, MS, LCGC
Cancer Genetic Counselor
Publications
Selected Publications
Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal E, Singh NA, Lancaster JM, Kurian AW. Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Accepted for publication January 2021, Cancer Prevention Research
Hall MJ. Updates in Chemoprevention Research for Hereditary Gastrointestinal and Polyposis Syndromes. Current Treatment Options in Gastroenterology. CTOG-D-20-00028R1. 8.2020.
Tricarico R, Nicolas E, Hall MJ, Golemis EA. X- and Y-linked chromatin-modifying genes as regulators of sex-specific cancer incidence and prognosis. Clin Cancer Res, 2020.
Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship Between MLH, PMS2, MSH2, and MSH6 Gene Specific Alternations and Tumor Mutation Burden (TMB) in 1,057 Microsatellite Instability-high Solid Tumors. Int J Cancer. 2020 May 24. doi: 10.1002/ijc.33115. [Epub ahead of print]. PMID: 32449172.
Hampel H, Chruch J, Dudley BR, Hall MJ, Stoffel E, Yurgelun MB, Kupfer S, Singh A, You YN, Mork ME, Stoll JLK. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position Statement on Multigene Panel Testing for Patients with Colorectal Cancer and/or Polyposis. Fam Cancer. 2020 Jul;19(3):223-239. doi: 10.1007/s10689-020-00170-9.PMID: 32172433
Biller L, Ukaegbu C, Dhingra T, Burke C, Chertock Y, Chittenden A, Church J, Koeppe E, Leach B, Levinson E, Lim R, Lutz M, Salo-Mullen E, Sheikh R, Idos G, Kastrinos F, Stoffel E, Weiss J, Hall MJ, Kalady M, Stadler Z, Syngal S, Yurgelun M. A Multi-Institutional Cohort of Therapy-associated Polyposis in Childhood and Young Adulthood Cancer Survivors. Canc Prev Res. 2020 Feb 12. Doi: 10.1158/1940-6207. CAPR-19-0416R1. PMID: 32051178.
Golan T et al, Hall MJ. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence with Metastatic Pancreatic Cancer Screened for Entry into the POLO Trial. Clin Oncol. 2020 Feb 19: JCO1901890. doi: 10.1200/JCO.19.01890. PMID: 32073954.
Jain R, Handorf E, Khare V, Blau M, Chertock Y, Hall MJ. Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants. Oncologist. 2020 Feb; 25 (2): 161-169. doi: 10.1634/theoncologist.2019-0289.Epub 2019 Nov 20. PMID: 32043776.
Nicolas E, Tricarico R, Savage M, Golemis EA, Hall MJ. Disease-Associated Genetic Variation in Human Mitochondrial Protein Import. American Journal of Human Genetics, 2019. PubMed
Golan T, Hammel P, Reni M, Van Cutsem E, Hall MJ, et all. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2. PMID: 31157963; PMCID: PMC6810605.
Hall MJ et al. The COGENT study group. Use and patient reported outcomes of clinical multi-gene panel testing for cancer susceptibility in the multi-center Communication of Genetic Test Results by Telephone Study. JCO Precision Oncology.Dec.2018.00199.
Gray PN, Tsai P, Chen D, Wu S, Hoo J, Hall MJ, et al. TumorNext-Lynch-MMR: A Comprehensive Next Generation Sequencing Assay for the Detection of Germline and Somatic Mutations in Genes Associated with Mismatch Repair Deficiency and Lynch Syndrome. Oncotarget. 2018 Apr 17;9(29):20304-20322. PMID: 29755653; PMCID: PMC5945525.
Shaikh T, Handorf EA, Meyer JE, Hall MJ, Esnaola NF. Mismatch Repair Deficiency Testing in Patients with Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol. 2018 Feb 8;4(2):e173580. PMID: 29121143; PMCID: PMC5838708.
Kurian AW, Hughes E, Handorf EA, Gutin, A, Allen B, Hartman AR, Hall, MJ. Breast and Ovarian Cancer Penetrance Estimates Derived from Germline Multiple –Gene Sequencing Results in Women. JCO Precision Oncology 2017. June 27.10.1200.00066.
Meyer JE, Cohen SJ, Ruth KJ, Sigurdson ER, Hall MJ. Young Age Increases Risk of Lymph Node Positivity in Early-Stage Rectal Cancer. J Natl Cancer Inst. 2016 Jan;108(1) PubMed PMID: 26719881; PubMed Central PMCID: PMC4715232
Arora S, Yan H, Cho I, Fan HY, Luo B, Gai X, Hall M, et al. Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes from a Subset of Patients With Familial Colorectal Carcinomas. Gastroenterology. 2015 Dec;149(7):1872-1883.e9. doi: 10.1053/j.gastro.2015.08.052. Epub 2015 Sep 5. PMID: 26344056; PMCID: PMC4663158.
Guindalini RS, Win AK, Gulden C, Lindor NM, Hall MH, et all. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov;149(6):1446-53. doi: 10.1053/j.gastro.2015.07.052. Epub 2015 Aug 3. PMID: 26248088; PMCID: PMC4648287.
Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Hall, MJ. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget. 2015 Nov 24;6(37):39614-33. doi: 10.18632/oncotarget.5554. PMID: 26485759; PMCID: PMC4741850.
Boland PM, Ruth K, Matro JM, Rainey KL, Fang CY, Wong YN, Daly MB, Hall MJ. Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing. Clin Genet. 2015 Dec;88(6):565-72. doi: 10.1111/cge.12555. Epub 2015 Jan 22. PMID: 25523111; PMCID: PMC4474774.
Hall MJ, Innocent J, Rybak CM, Veloski C, Scott WJ, et all. Case Report: Bilateral granulosa cell carcinoma: A novel malignant manifestation of MEN1 syndrome associated with a rare intronic deletion. Appl Clin Gen 2014. PubMed
Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB. Understanding patient and provider perceptions and expectations of genomic medicine. J Surg Oncol. 2015 Jan;111(1):9-17. doi: 10.1002/jso.23712. Epub 2014 Jul 3. PMID: 24992205; PMCID: PMC4286413.
Bradbury AR, Patrick-Miller L, Long J, Stopfer J, Hall MJ et all. Development of a tiered and binned counseling model for informed consent in the era of multiplex testing for cancer susceptibility Genet Med. 2014 Oct 9. PubMed
Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014 Sep;12(9):1339-1346. PubMed
Hall MJ. Conflicted Confidence: Academic Oncologists' Views on Multiplex Pharmacogenomic Testing. J Clin Oncol. 2014 Mar 24. PubMed
Hall MJ, Herda MM, Handorf EA, Rybak CC, Keleher CA, Siemon M, Daly MB. Direct access to universal mismatch repair (MMR) screening results for Lynch syndrome (LS) via electronic personal health record (ePHR):A feasibility study. Genet Med. 2014 May 1.
Matro JM, Ruth KJ, Wong YN, McCully KC, Rybak CM, Meropol NJ, Hall MJ. Cost-sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing. J Genet Couns. 2014 May 6.
Hall MJ, Manne SL, Myers RE, Keenan EM, Balshem AM, Weinberg DS. Association of knowledge and race to gene environment risk assessment (GERA) testing for colorectal cancer Genome Med 2012;4(11):92 [epub ahead of print] PMID: 23194586.
Hall MJ, Ruth K, Giri VN. Predictors of compliance with age-appropriate colorectal cancer screening in men enrolled in a prostate cancer screening program. Cancer 2012 Jan 15;118(2):478-84.
Additional Publications
Related Articles
22 PATIENT COMMENTS
-
5.0
January 15, 2021
I have had extremely positive interactions with Dr Hall and everyone his office. I am grateful for their care and kindness.
-
5.0
January 13, 2021
dr. Hall is a compassionate, kind and informative man.
-
5.0
January 07, 2021
Dr. Hall & his staff are superb.
-
5.0
December 20, 2020
Dr. Hall is always good to work with, and very helpful in presenting valuable options for managing my health.
-
5.0
November 17, 2020
Dr. Hall & Dr. [...] are excellent drs.
-
5.0
November 01, 2020
excellent experience!!
-
5.0
August 16, 2020
The best healthcare I can ever have. Thank you.
-
5.0
June 25, 2020
I absolutely love Fox Chase and my team there!! I recommend Fox Chase to everyone who is faced with a cancer diagnosis or who has a loved one diagnosed with cancer!!Dr. Hall is an amazing doctor and I am 100% confident in his treatment plans and his responses to all my questions and concerns!!
-
5.0
June 24, 2020
Treated like a family member and were very concerned for my needs.
-
5.0
June 23, 2020
Dr.Hall is the best!! He took excellent care of me during the past five years.
-
5.0
May 28, 2020
Dr Hall and his staff are excellent! I feel very confident that I have the best care team possible . Dr Hall always goes above and beyond to address my concerns and explains things in laymen's term to where I have a clear understanding. His compassion, kindness and understanding are like no other doctor I have ever met with. [...] will always recommend him to anyone I can!
-
5.0
May 27, 2020
always a wonderful experience!
-
5.0
January 23, 2020
A+.
-
5.0
January 19, 2020
Very good experience
-
5.0
November 24, 2019
it was a wonderful experience, as usual!!
-
5.0
November 17, 2019
The team at Fox Chase is the best Dr. Hall & [...] & staff can't ask for anything better thanks.
-
5.0
November 17, 2019
The care I have received over the years was excelllent! I am so blessed to be cancer free for 5 years!
-
5.0
November 05, 2019
Very good experience.
-
5.0
November 04, 2019
Excellent care from Dr. Hall, nurses, and staff at reception desk.
-
5.0
October 24, 2019
Dr Hall is an excellent doctor and I'm lucky to be in his care
LOAD MORE